Alzheimer's disease (AD) is characterized by extraneuronal plaques consisting of b-amyloid (A?) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated, paired helical filaments of the microtubule-associated protein, tau. Multiple lines of evidence suggest that overproduction of A? in the brain is a major cause of AD, whereas hyperphosphorylated tau has been found in many neurodegenerative diseases known as tauopathies. Hence, identification of new genes/proteins involved in these processes is a major goal in AD research and may provide potential therapeutic targets. In the previous funding period, we applied the random homozygous gene perturbation (RHGP) technology to screen for genes involved in A? generation and identified a novel mouse gene, Rps23r1(previously named Fg01 in the original submission). Overexpression of the RPS23R1 protein can significantly reduce A? generation, tau phosphorylation and GSK-3 activity. Further in vitro studies showed that RPS23R1 interacts with adenylate cyclases, increasing cAMP synthesis, which upregulates PKA activity. Both activation of PKA and inactivation of GSK-3 are known to inhibit A? generation and GSK-3 inactivation also inhibits tau phosphorylation. The function of Rps23r1 was also demonstrated in transgenic mice expressing brain-specific Rps23r1. Furthermore, the AD-like pathologies of the APP/PS1/tau triple transgenic AD mice were ameliorated and levels of synaptic marker proteins were increased after crossing the mice with the Rps23r1 transgenic mice. Although Rps23r1 is a unique mouse gene, Rps23r1 produces the same phenotype in cells of various species including human. Rps23r1 originated through mouse Rps23 (ribosomal protein S23) mRNA retroposition, a process where mRNA is reintegrated into the genome resulting in gene duplication/evolution. Since Rps23 retroposition also occurred in humans, it is possible that humans possess functional Rps23r1 homologs. Our results suggest that RPS23R1- and functional human RPS23R1 homolog-mediated signaling pathways may play important roles in the pathogenesis of AD and other diseases, such as cancer and diabetes, in which PKA and GSK-3 are crucially involved. Therefore, in this competitive renewal proposal we aim to determine the functional domain(s) of RPS23R1, identify functional human Rps23r1 homologs, further characterize RPS23R1 and its human homologs and decipher mechanisms underlying their effects, specifically inhibition of A generation, tau phosphorylation and modulation of GSK-3 activity. We will cross brain-specific Rps23r1 transgenic mice with AD transgenic (Tg2576 and APP/PS1/tau triple) mice to determine whether Rps23r1 can ameliorate AD-like pathologies and behavioral/cognitive deficits. We will also generate Rps23r1 conditional knockout mice to explore other physiological functions of Rps23r1. The results of these studies are expected to provide important information for developing new strategies to combat AD and other diseases.

Public Health Relevance

Alzheimer's disease (AD) is a devastating neurodegenerative disease characterized by extraneuronal plaques resulting from Ab and NFTs caused by tau phosphorylation. Our identification of the novel gene, Rps23r1, and the molecular pathway/mechanism by which it reduces Ab generation and tau phosphorylation, is expected to have a significant impact on basic research and development of new strategies for treating AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG021173-09
Application #
8811900
Study Section
Cell Death in Neurodegeneration Study Section (CDIN)
Program Officer
Miller, Marilyn
Project Start
2002-07-01
Project End
2016-02-29
Budget Start
2015-03-01
Budget End
2016-02-29
Support Year
9
Fiscal Year
2015
Total Cost
$387,757
Indirect Cost
$188,907
Name
Sanford-Burnham Medical Research Institute
Department
Type
DUNS #
020520466
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Lee, C Y Daniel; Daggett, Anthony; Gu, Xiaofeng et al. (2018) Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models. Neuron 97:1032-1048.e5
Du, Ying; Zhao, Yingjun; Li, Chuan et al. (2018) Inhibition of PKC? reduces amyloid-? levels and reverses Alzheimer disease phenotypes. J Exp Med 215:1665-1677
Zhao, Dongdong; Meng, Jian; Zhao, Yingjun et al. (2018) RPS23RG1 Is Required for Synaptic Integrity and Rescues Alzheimer's Disease-Associated Cognitive Deficits. Biol Psychiatry :
Zhang, Hongfeng; Huang, Timothy; Hong, Yujuan et al. (2018) The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases. Front Aging Neurosci 10:79
Simandi, Zoltan; Pajer, Krisztian; Karolyi, Katalin et al. (2018) Arginine Methyltransferase PRMT8 Provides Cellular Stress Tolerance in Aging Motoneurons. J Neurosci 38:7683-7700
Zhao, Yingjun; Wu, Xilin; Li, Xiaoguang et al. (2018) TREM2 Is a Receptor for ?-Amyloid that Mediates Microglial Function. Neuron 97:1023-1031.e7
Zhao, Yingjun; Li, Xiaoguang; Huang, Timothy et al. (2017) Intracellular trafficking of TREM2 is regulated by presenilin 1. Exp Mol Med 49:e405
Zhu, Bing; Jiang, LuLin; Huang, Timothy et al. (2017) ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating ?-secretase activity. Nat Commun 8:1472
Wu, Xi-Lin; Piña-Crespo, Juan; Zhang, Yun-Wu et al. (2017) Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. Chin Med J (Engl) 130:2978-2990
Huang, Timothy Y; Zhao, Yingjun; Jiang, Lu-Lin et al. (2017) SORLA attenuates EphA4 signaling and amyloid ?-induced neurodegeneration. J Exp Med 214:3669-3685

Showing the most recent 10 out of 60 publications